| Literature DB >> 29675622 |
Rosana Quintana1,2,3, Mario Goñi4, Nora Mathern5, Marisa Jorfen4, Silvana Conti6, Romina Nieto6, Alvaro Sanabria6, Cristina Prigione6, Adriana M R Silvestre7, Vanina García7, Guillermo Pons-Estel6,8,9, Ricard Cervera8, Conrado García10, Ingris Peláez-Ballestas10, Graciela S Alarcón11, Bernardo A Pons-Estel6,9.
Abstract
To describe the baseline and follow up epidemiological/clinical characteristics of rheumatoid arthritis (RA) in a community-based cohort of the qom population. RA (ACR criteria) patients identified (n = 40) or not (n = 25) in the previous study were included. Baseline and follow-up visits (3, 6, and 12 months) were performed. Treatment adherence and modification, disability (Health Assessment Questionnaire Disability Index-HAQ-DI), and Disease Activity [DAS-28 (ESR)] were ascertained. At 12 months, complete and incomplete lost to follow-up patients were identified. The estimated RA prevalence was 3%. The patients' mean (SD) disease duration was 110.5 (17.9) and their median delay in diagnosis 30.4 (IQR 52.8) months; mean (SD) age and years of formal education were 39.8 (1.6) and 5.3 (SD 0.3); 58 (89.2%) were female, and 89.2% were seropositive. At baseline, their mean DAS-28 (ESR) was 4.8 (SD 0.9) with 67.7% having high disease activity and 32.3% moderate; 76.9% reported HAQ-DI ≥ 0.8. At 12 months, three patients have died; 13 (20.9%) were "completely" and 19 (30.6%) "incompletely" lost to follow-up. There were favorable changes over time for disease activity (p ˂ 0.001), HAQ-DI (p ˂ 0.001), and treatment modifications (p ˂ 0.001) but no changes in treatment adherence (p = 0.260). The main cause of lost to follow-up was migration. This population has one of the highest RA prevalence rate reported. Patients had an aggressive and disabling disease, with poor adherence to treatment. Improvements of clinical parameters over time were observed.Entities:
Keywords: Community-based cohort; Indigenous community; Latin America; Rheumatoid arthritis; Treatment adherence; qom
Mesh:
Year: 2018 PMID: 29675622 DOI: 10.1007/s10067-018-4103-5
Source DB: PubMed Journal: Clin Rheumatol ISSN: 0770-3198 Impact factor: 2.980